Jefferies initiated coverage on biote Corp.
$BTMD
Medicinal Chemicals and Botanical Products
Health Care
Jefferies initiated coverage of biote Corp. with a rating of Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2025 | $4.00 | Buy → Neutral | B. Riley Securities |
| 12/16/2024 | Buy | Craig Hallum | |
| 2/20/2024 | $9.00 | Buy | B. Riley Securities |
| 2/1/2024 | Buy | Jefferies |
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
B. Riley Securities downgraded biote Corp. from Buy to Neutral and set a new price target of $4.00
Craig Hallum initiated coverage of biote Corp. with a rating of Buy
B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
8-K - biote Corp. (0001819253) (Filer)
8-K - biote Corp. (0001819253) (Filer)
SCHEDULE 13G/A - biote Corp. (0001819253) (Subject)
Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro
Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting
Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners
Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights Revenue of $44.9 million Gross profit margin of 68.9% Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37 in the first quarter of 2025 Adjusted EBITDA1 of $8.7 million and Adjusted EBITDA margin1 of 19.4% Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners' patients, today announced the Company will provide first quarter financial results on Wednesday, May 6, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be avai
Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights Revenue of $46.4 million Gross profit margin of 68.0% Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the fourth quarter of 2024 Adjusted EBITDA1 of $11.7 million and Adjusted EBITDA margin1 of 25.2% Full Year 2025 Financial Highlights Revenue of $192.2 million
Biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital, overseeing quality and safety programs across a large, complex healthcare system serving appro
Bret Christensen Stepping Down as CEO for Family and Personal Reasons, Remains a Director Company Reaffirms Full Year 2026 Guidance Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman. Commenting
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)